Recently listed, Satellos Bioscience Inc.
(NASDAQ:MSLE) on Wednesday reported six-month interim data from its ongoing TRAILHEAD study of SAT-3247 for Duchenne muscular dystrophy (DMD) The data showed that SAT-3247-treated DMD patients experienced improvements in muscle composition and upper limb activity while maintaining stable strength.
The company also said the drug continued to demonstrate a favorable safety and tolerability profile, supporting its continued clinical development.
Read Also: Sarepta Moves Closer To FDA Approval For Duchenne Muscular Dystrophy Drugs The TRAILHEAD study is expected to enroll up to 30 male participants.
SAT-3247 Shows Improvements In Muscle Composition And Upper Limb Activity The interim analysis included four adults between the ages of 21 and 28 who had previously completed the Phase 1a/b CL-101 study.
